PharmaShots | Incisive News in 3 Shots

Subscribe Now

reSURFACE 1

Sun Pharma Reports Five Year Results of Ilumya (tildrakizumab-asmn) in P-III Studies for Moderate-to-Severe Plaque Psoriasis

Sun Pharma Reports Five Year Results of Ilumya (tildrakizumab-asmn) in P-III Studies for Moderate-to-Severe Plaque Psoriasis

November 2, 2020

Sun Pharma Reports Four Years Result of Ilumya (tildrakizumab-asmn) in P-III reSURFACE 1 and 2 Trials in Patients with Moderate-to-Severe Plaque Psoriasis

Sun Pharma Reports Four Years Result of Ilumya (tildrakizumab-asmn) in P-III reSURFACE 1 and 2 Trials in Patients with Moderate-to...

October 10, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us